Byler syndromeK74.5

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 29.10.2020

Dieser Artikel auf Deutsch

Synonym(s)

Byler's disease; Cholestasis, fatal intrahepatic type 1; Familial intrahepatic cholestasis associated protein type 1; FIC1; Orpha 79306; Progressive familial intrahepatic cholestasis 1 (e); Progressive familial intrahepatic cholestasis type PFIC1

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

Rare, congenital cholestatic liver disease. It is also known as progressive familial intrahepatic cholestasis type PFIC1.

Occurrence/EpidemiologyThis section has been translated automatically.

The prevalence of PFIC types 1-3 is 1:50,000 to 1: 100,000 births. PFIC1 < PFIC2 and PFIC3.

Clinical featuresThis section has been translated automatically.

The disease is already registered in early infancy. Signs of cholestasis: discoloured stools, dark urine, recurrent or permanent icterus, hepatomegaly and severe itching. Patients develop progressive cirrhosis of the liver at an early stage. Extrahepatic symptoms have been reported, including persistent short stature, watery diarrhoea, pancreatitis and sensorineural deafness.

HistologyThis section has been translated automatically.

Channelicular cholestasis; no ductal proliferations.

DiagnosisThis section has been translated automatically.

Cholangiography: normal biliary system. Prenatal diagnosis is recommended if both parents have a mutated gene.

TherapyThis section has been translated automatically.

The treatment of Byler's syndrome consists of a liver transplantation (partial liver transplantation) in about 50% of those affected. It leads to a cure.

Ursodesoxycholic acid: Ursodesoxycholic acid can be used as a bridging agent to slow down the progress of the disease.

MCT diet (diet with medium-chain triglycerides. MCT=Acronym for "medium-chain triglycerides"). improves the absorption of fat and fat-soluble vitamins.

The itching can be reduced by Rifampicin

Progression/forecastThis section has been translated automatically.

Without a liver transplant, the prognosis is poor. Only few children reach the age of 10 years.

LiteratureThis section has been translated automatically.

  1. Keitel V et al (2019) Targeting FXR in cholestasis. Handb Exp Pharmacol doi: 10.1007/164_2019_231.
  2. Vitale G et al (2019) Familial intrahepatic cholestasis: New and wide perspectives. Dig Liver Dis 51:922-933.

Authors

Last updated on: 29.10.2020